US 12,109,229 B2
Treatment of neurodegenerative disease with sodium chlorite
Vernon A. Norviel, San Diego, CA (US); and Michael S. McGrath, Meadow Vista, CA (US)
Assigned to NEUVIVO, INC., Palo Alto, CA (US); and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by Neuvivo, Inc., Palo Alto, CA (US); and The Regents of the University of California, Oakland, CA (US)
Filed on Feb. 14, 2024, as Appl. No. 18/441,600.
Application 18/441,600 is a continuation of application No. 18/095,199, filed on Jan. 10, 2023, granted, now 11,938,148.
Application 18/095,199 is a continuation of application No. 17/823,489, filed on Aug. 30, 2022, granted, now 11,938,147.
Application 17/823,489 is a continuation of application No. 15/772,317, abandoned, previously published as PCT/US2016/059915, filed on Nov. 1, 2016.
Claims priority of provisional application 62/249,846, filed on Nov. 2, 2015.
Prior Publication US 2024/0261324 A1, Aug. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/20 (2006.01); A61P 25/28 (2006.01)
CPC A61K 33/20 (2013.01) [A61P 25/28 (2018.01)] 14 Claims
 
1. A method comprising:
a) administering to a subject who has dementia a regimen of sodium chlorite; and
b) monitoring a plasma level of C-reactive protein in the subject during the regimen of sodium chlorite and determining based on the monitoring that the plasma level of C-reactive protein in the subject is at least 1125 ng/mL.